What happened in this episode?
Dr David Sinclair, a Harvard researcher known for ageing and epigenetics work, tells Chris Williamson that his lab’s partial Yamanaka-factor approach to “epigenetic reprogramming” has moved into human testing, beginning with gene therapy delivered to the eye, which he describes as a safer, enclosed site. He also claims his group has developed an orally delivered “cocktail” that produces rejuvenation-like effects in old mice and says early evidence implicates TET enzymes and epigenetic reset pathways, though he acknowledges the precise mechanism is not fully understood.
Sinclair argues ageing should be treated like a disease to unlock prevention and therapeutics, and makes a specific prediction that the first person to live to 150 is already alive. He discusses the contested public narrative around resveratrol and NAD precursors, including his account of past scientific disputes and his view that boosting NAD is beneficial even if some cell types do not show age-related NAD decline.
On supplements regulation and quality, he recounts that lawyers for MetroBiotech contacted the FDA about NMN being sold while in clinical trials, despite his stated objections, and says the position later shifted following a court case. He also alleges NMN products can be contaminated — including endotoxin — and says his lab encountered this issue during mouse work. Sinclair additionally describes how AI is speeding up discovery in his lab, including work he says would previously have taken decades.
Lifestyle advice in the episode centres on weight control, resistance and aerobic training, sleep quality, and stress management, alongside a cautious appraisal of popular biohacking interventions such as sauna and cold exposure and growing interest in GLP-1 drugs’ broader effects.
